{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2007"],"condition":["Metastatic Colorectal Cancer","Metastatic colorectal cancer"],"disease":["Metastatic Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2522328"],"location":["Austria"],"study_start_month":["8"],"keyword":["Xeloda","Tarceva","Avastin"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Phase III study of an optimized chemotherapy + Avastin strategy +/- Tarceva in metastatic colorectal cancer.","description":"Primary objectives: To show superiority in Progression Free Survival (PFS) from the date of randomization with Avastin plusTarceva compared to Avastin alone.","dates":{"creation":"2007-08-15"},"accession":"2522328","cross_references":{"EU Clinical Trials Register":["2007-002797-56"]}}